PURPOSE: Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia. METHODS: A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score. RESULTS: Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, 0.14-0.95) was significantly associated with decreased mortality at 48 hours after admission. CONCLUSION: Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies.
PURPOSE: Although numerous articles have demonstrated that recommended empiric antimicrobial regimens are associated with decreased mortality at 30 days, there is controversy over whether appropriate antibiotic selection has a beneficial impact on mortality within the first 48 to 96 hours after admission. Our aim was to determine whether the use of guideline-concordant antibiotic therapy is associated with decreased mortality within the first 48 hours after admission for patients with pneumonia. METHODS: A retrospective cohort study was conducted at two tertiary teaching hospitals in San Antonio, Texas. A propensity score was used to balance the covariates associated with the use of guideline-concordant antimicrobial therapy. A multivariable logistic regression model was used to assess the association between mortality within 48 hours and the use of guideline-concordant antibiotic therapy, after adjusting for potential confounders including the propensity score. RESULTS: Information was obtained on 787 patients with community-acquired pneumonia. The median age was 60 years, 79% were male, and 20% were initially admitted to the intensive care unit. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk. Within the first 48 hours, 20 patients died. After adjustment for potential confounders, the use of guideline-concordant antimicrobial therapy (odds ratio 0.37, 95% confidence interval, 0.14-0.95) was significantly associated with decreased mortality at 48 hours after admission. CONCLUSION: Using initial empiric guideline-concordant antimicrobial therapy is associated with decreased mortality at 48 hours. Further research needs to investigate methods to ensure that patients with community-acquired pneumonia are treated with appropriate antimicrobial therapies.
Authors: Sara Tomczyk; Seema Jain; Anna M Bramley; Wesley H Self; Evan J Anderson; Chris Trabue; D Mark Courtney; Carlos G Grijalva; Grant W Waterer; Kathryn M Edwards; Richard G Wunderink; Lauri A Hicks Journal: Open Forum Infect Dis Date: 2017-06-20 Impact factor: 3.835
Authors: Ana Motos; Gianluigi Li Bassi; Francesco Pagliara; Laia Fernandez-Barat; Hua Yang; Eli Aguilera Xiol; Tarek Senussi; Francesco A Idone; Chiara Travierso; Chiara Chiurazzi; Rosanel Amaro; Minlan Yang; Joaquim Bobi; Montserrat Rigol; David P Nicolau; Gerard Frigola; Roberto Cabrera; Jose Ramirez; Paolo Pelosi; Francesco Blasi; Massimo Antonelli; Antonio Artigas; Jordi Vila; Marin Kollef; Antoni Torres Journal: Antimicrob Agents Chemother Date: 2021-01-20 Impact factor: 5.191
Authors: Dragos C Zaharia; Cezar Iancu; Alexandru T Steriade; Alexandru A Muntean; Octavian Balint; Vlad T Popa; Mircea I Popa; Miron A Bogdan Journal: BMC Microbiol Date: 2010-12-17 Impact factor: 3.605
Authors: Rosario Menéndez; Antoni Torres; Soledad Reyes; Rafael Zalacain; Alberto Capelastegui; Olga Rajas; Luis Borderías; Juan J Martín-Villasclaras; Salvador Bello; Inmaculada Alfageme; Felipe Rodríguez de Castro; Jordi Rello; Luis Molinos; Juan Ruiz-Manzano Journal: PLoS One Date: 2012-05-22 Impact factor: 3.240
Authors: Mathieu Bangert; Adam K Wright; Jamie Rylance; Matthew J Kelly; Angela D Wright; George M Carlone; Jacquelyn S Sampson; Gowrisankar Rajam; Edwin W Ades; Aras Kadioglu; Stephen B Gordon Journal: Antimicrob Agents Chemother Date: 2013-07-01 Impact factor: 5.191